Andriy Krendyukov

Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)

Matti Aapro, Heinz Ludwig, Carsten Bokemeyer et al. · Annals of Oncology · 2016 · 35 citations · Full text

Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?

David Goldsmith, Frank Dellanna, Martin Schiestl et al. · Clinical Drug Investigation · 2018 · 30 citations · Full text

Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study)

Matti Aapro, Carsten Bokemeyer, Heinz Ludwig et al. · Journal of Geriatric Oncology · 2016 · 24 citations · Full text

Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy

Kimberly Blackwell, Pere Gascón, Andriy Krendyukov et al. · Annals of Oncology · 2017 · 23 citations · Full text

Hematological Malignancy, Medicine, Phase Iii +6

Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study

Carsten Bokemeyer, Pere Gascón, Matti Aapro et al. · Supportive Care in Cancer · 2017 · 22 citations · Full text